Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement

Disease Markers

Volumn 35, Issue 6, 2013, Pages 857-862

  Cai, Anping ^a   Li, Liwen ^a   Zhang, Ying ^a   Mo, Yujin ^a   Li, Zhigen ^a   Mai, Weiyi ^b   Zhou, Yingling ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RESTENOSIS; STENT;

AGED; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DISEASE PROGRESSION; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RISK; STENTS; TREATMENT OUTCOME;

EID: 84896976609     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/472845     Document Type: Article

References (27)

1. Reiner Z., Catapano A. L., De Backer G., ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011 32 14 1769 1818
2. Gibson C. M., Pride Y. B., Hochberg C. P., Sloan S., Sabatine M. S., Cannon C. P., Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. Journal of the American College of Cardiology 2009 54 24 2290 2295 2-s2.0-70549111032 10.1016/j.jacc.2009.09.010
3. Armitage J., Bowman L., Wallendszus K., Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. The Lancet 2010 376 9753 1658 1669
4. Baigent C., Blackwell L., Emberson J., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet 2010 376 9753 1670 1681
5. Ohira T., Schreiner P. J., Morrisett J. D., Chambless L. E., Rosamond W. D., Folsom A. R., Lipoprotein(a) and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 2006 37 6 1407 1412 2-s2.0-33745127392 10.1161/01.STR.0000222666.21482.b6
6. Cannon C. P., Braunwald E., McCabe C. H., Rader D. J., Rouleau J. L., Belder R., Joyal S. V., Hill K. A., Pfeffer M. A., Skene A. M., Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004 350 15 1495 1504 2-s2.0-11144355354 10.1056/NEJMoa040583
7. LaRosa J. C., Grundy S. M., Waters D. D., Shear C., Barter P., Fruchart J.-C., Gotto A. M., Greten H., Kastelein J. J. P., Shepherd J., Wenger N. K., Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 2005 352 14 1425 1435 2-s2.0-15944410609 10.1056/NEJMoa050461
8. Pedersen T. R., Faergeman O., Kastelein J. J. P., Olsson A. G., Tikkanen M. J., Holme I., Larsen M. L., Bendiksen F. S., Lindahl C., Szarek M., Tsai J., High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized controlled trial. Journal of the American Medical Association 2005 294 19 2437 2445 2-s2.0-27744603499 10.1001/jama.294.19.2437
9. Nordestgaard B. G., Chapman M. J., Ray K., Borén J., Andreotti F., Watts G. F., Ginsberg H., Amarenco P., Catapano A., Descamps O. S., Fisher E., Kovanen P. T., Kuivenhoven J. A., Lesnik P., Masana L., Reiner Z., Taskinen M.-R., Tokgözoglu L., Tybjærg-Hansen A., Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 2010 31 23 2844 2853 2-s2.0-78649888517 10.1093/eurheartj/ehq386
10. Tsimikas S., Hall J. L., Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. Journal of the American College of Cardiology 2012 60 8 716 721
11. Clarke R., Peden J. F., Hopewell J. C., Kyriakou T., Goel A., Heath S. C., Parish S., Barlera S., Franzosi M. G., Rust S., Bennett D., Silveira A., Malarstig A., Green F. R., Lathrop M., Gigante B., Leander K., De Faire U., Seedorf U., Hamsten A., Collins R., Watkins H., Farrall M., Genetic variants associated with Lp(a) lipoprotein level and coronary disease. The New England Journal of Medicine 2009 361 26 2518 2528 2-s2.0-73549097512 10.1056/NEJMoa0902604
12. Cai A., Li W., Zhang Y., Mo Y., Mai W., Zhou Y., Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. Disease Markers 2013 35 5 551 559
13. Berglund L., Ramakrishnan R., Lipoprotein(a): an elusive cardiovascular risk factor. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 12 2219 2226 2-s2.0-10644264549 10.1161/01.ATV.0000144010.55563.63
14. Kamstrup P. R., Lipoprotein(a) and ischemic heart disease-A causal association? A review. Atherosclerosis 2010 211 1 15 23 2-s2.0-77954312278 10.1016/j.atherosclerosis.2009.12.036
15. Kamstrup P. R., Benn M., Tybjærg-Hansen A., Nordestgaard B. G., Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008 117 2 176 184 2-s2.0-38049177286 10.1161/CIRCULATIONAHA.107.715698
16. Luc G., Bard J.-M., Arveiler D., Ferrieres J., Evans A., Amouyel P., Fruchart J.-C., Ducimetiere P., Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis 2002 163 2 377 384 2-s2.0-0036269884 10.1016/S0021-9150(02)00026-6
17. Danik J. S., Rifai N., Buring J. E., Ridker P. M., Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. Journal of the American Medical Association 2006 296 11 1363 1370 2-s2.0-33748904095 10.1001/jama.296.11.1363
18. Cantin B., Gagnon F., Moorjani S., Després J.-P., Lamarche B., Lupien P.-J., Dagenais G. R., Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study. Journal of the American College of Cardiology 1998 31 3 519 525 2-s2.0-18144438859 10.1016/S0735-1097(97)00528-7
19. Danesh J., Collins R., Peto R., Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000 102 10 1082 1085 2-s2.0-0034609562
20. Momiyama Y., Ohmori R., Fayad Z. A., Tanaka N., Kato R., Taniguchi H., Nagata M., Ohsuzu F., Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis. Atherosclerosis 2012 222 1 241 244 2-s2.0-84859812998 10.1016/j.atherosclerosis.2012.02.008
21. Nicholls S. J., Tang W. H. W., Scoffone H., Brennan D. M., Hartiala J., Allayee H., Hazen S. L., Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. Journal of Lipid Research 2010 51 10 3055 3061 2-s2.0-77956849517 10.1194/jlr.M008961
22. Virani S. S., Brautbar A., Davis B. C., Nambi V., Hoogeveen R. C., Sharrett A. R., Coresh J., Mosley T. H., Morrisett J. D., Catellier D. J., Folsom A. R., Boerwinkle E., Ballantyne C. M., Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2012 125 2 241 249 2-s2.0-84856101806 10.1161/CIRCULATIONAHA.111.045120
23. Tsimikas S., Witztum J. L., The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Current Opinion in Lipidology 2008 19 4 369 377 2-s2.0-53149102508 10.1097/MOL.0b013e328308b622
24. Hoover-Plow J., Huang M., Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2013 62 4 479 491
25. Grainger D. J., Kemp P. R., Liu A. C., Lawn R. M., Metcalfe J. C., Activation of transforming growth factor- β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994 370 6489 460 462 2-s2.0-0027989926 10.1038/370460a0
26. Kronenberg F., Kronenberg M. F., Kiechl S., Trenkwalder E., Santer P., Oberhollenzer F., Egger G., Utermann G., Willeit J., Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the bruneck study. Circulation 1999 100 11 1154 1160 2-s2.0-0033554451
27. Spence J. D., Koschinsky M., Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 7 1550 1551